全文获取类型
收费全文 | 802篇 |
免费 | 67篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 16篇 |
妇产科学 | 22篇 |
基础医学 | 73篇 |
口腔科学 | 10篇 |
临床医学 | 95篇 |
内科学 | 179篇 |
皮肤病学 | 5篇 |
神经病学 | 52篇 |
特种医学 | 128篇 |
外科学 | 151篇 |
综合类 | 17篇 |
预防医学 | 49篇 |
眼科学 | 9篇 |
药学 | 27篇 |
中国医学 | 4篇 |
肿瘤学 | 32篇 |
出版年
2021年 | 6篇 |
2020年 | 10篇 |
2019年 | 15篇 |
2018年 | 17篇 |
2017年 | 15篇 |
2016年 | 13篇 |
2015年 | 21篇 |
2014年 | 21篇 |
2013年 | 20篇 |
2012年 | 37篇 |
2011年 | 33篇 |
2010年 | 24篇 |
2009年 | 12篇 |
2008年 | 37篇 |
2007年 | 33篇 |
2006年 | 39篇 |
2005年 | 26篇 |
2004年 | 28篇 |
2003年 | 22篇 |
2002年 | 23篇 |
2001年 | 21篇 |
2000年 | 27篇 |
1999年 | 31篇 |
1998年 | 35篇 |
1997年 | 18篇 |
1996年 | 24篇 |
1995年 | 23篇 |
1994年 | 17篇 |
1993年 | 17篇 |
1992年 | 15篇 |
1991年 | 23篇 |
1990年 | 11篇 |
1989年 | 16篇 |
1988年 | 11篇 |
1987年 | 7篇 |
1986年 | 11篇 |
1985年 | 10篇 |
1984年 | 5篇 |
1983年 | 5篇 |
1982年 | 8篇 |
1981年 | 4篇 |
1980年 | 10篇 |
1979年 | 7篇 |
1978年 | 4篇 |
1977年 | 4篇 |
1976年 | 8篇 |
1957年 | 6篇 |
1956年 | 4篇 |
1955年 | 4篇 |
1954年 | 5篇 |
排序方式: 共有872条查询结果,搜索用时 15 毫秒
131.
132.
133.
134.
135.
136.
137.
We examined the role of nitric oxide in N-methyl-d-aspartate (NMDA) receptor-mediated neurotoxicity in rat and mouse primary cortical cell cultures. In rat and mouse cultures, the NO synthase inhibitor, NG-Nitro-l-arginine, blocked cGMP formation but not neuronal cell death following a 5–10 min exposure to 300–500 μM NMDA. NG-Monomethyl-l-arginine was also unable to prevent neuronal death. In contrast, the non-competitive NMDA receptor antagonist, dextrophan, prevented both cGMP formation and cell death. While other data suggest that the synthesis of nitric oxide can mediate NMDA receptor-mediated neurotoxicity, present results suggest that such synthesis is not necessarily required. 相似文献
138.
A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. 总被引:12,自引:6,他引:6 下载免费PDF全文
J C Tardiff S M Factor B D Tompkins T E Hewett B M Palmer R L Moore S Schwartz J Robbins L A Leinwand 《The Journal of clinical investigation》1998,101(12):2800-2811
Mutations in multiple cardiac sarcomeric proteins including myosin heavy chain (MyHC) and cardiac troponin T (cTnT) cause a dominant genetic heart disease, familial hypertrophic cardiomyopathy (FHC). Patients with mutations in these two genes have quite distinct clinical characteristics. Those with MyHC mutations demonstrate more significant and uniform cardiac hypertrophy and a variable frequency of sudden death. Patients with cTnT mutations generally exhibit mild or no hypertrophy, but a high frequency of sudden death at an early age. To understand the basis for these distinctions and to study the pathogenesis of the disease, we have created transgenic mice expressing a truncated mouse cTnT allele analogous to one found in FHC patients. Mice expressing truncated cTnT at low (< 5%) levels develop cardiomyopathy and their hearts are significantly smaller (18-27%) than wild type. These animals also exhibit significant diastolic dysfunction and milder systolic dysfunction. Animals that express higher levels of transgene protein die within 24 h of birth. Transgenic mouse hearts demonstrate myocellular disarray and have a reduced number of cardiac myocytes that are smaller in size. These studies suggest that multiple cellular mechanisms result in the human disease, which is generally characterized by mild hypertrophy, but, also, frequent sudden death. 相似文献
139.
F M Hewett 《Pediatric clinics of North America》1973,20(3):695-704
140.
J H Bauer G P Reams J Hewett D Klachko A Lau C Messina V Knaus 《American journal of kidney diseases》1992,20(5):443-457
It is unknown if the antiproteinuric effect of angiotensin-converting enzyme (ACE) inhibitors reflects attenuation in the rate of progression of diabetic nephropathy. We report the results of a randomized, double-blind clinical trial designed to evaluate the longitudinal (18-month) effect of the ACE inhibitor, enalapril (5 to 40 mg/d), versus a placebo on 24-hour urinary protein excretion and on the rate of progression of renal disease in 33 patients with clinical diabetic nephropathy. Systemic blood pressure was controlled throughout the trial with conventional antihypertensive drugs. Glomerular filtration rate (GFR), determined by Tc99mDTPA renal clearance, and urinary protein excretion were monitored at 3-month intervals. Enalapril, in contrast to placebo therapy, was associated with an initial (40%) and sustained (33%) decrease in urinary protein excretion. Patients randomized to both enalapril or placebo experienced mean decreases in GFR, from 1.01 mL/s/1.73 m2 (61 mL/min/1.73 m2) to 0.85 mL/s/1.73 m2 (51 mL/min/1.73 m2), and from 1.06 mL/s/1.73 m2 (64 mL/min/1.73 m2) to 0.97 mL/s/1.73 m2 (58 mL/min/1.73 m2), respectively. Eleven of 18 patients (61%) randomized to enalapril, and 10 of 15 (66%) patients randomized to placebo, had a decrease in GFR; their rates of progression were -1.18 mL/min/1.73 m2/mo and -1.00 mL/min/1.73 m2/mo, respectively. In the absence of changes in blood pressure, the addition of an ACE inhibitor to patients with clinical diabetic nephropathy could not be shown to confer a unique renal protective effect. A prolonged decrease in 24-hour protein excretion could not be shown to predict attenuation in the progression of established clinical diabetic nephropathy. 相似文献